Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a publicly traded Healthcare sector company. As of May 21, 2026, ARTV trades at $7.81 with a market cap of $447.98M and a P/E ratio of -2.27. ARTV moved -8.60% today. Year to date, ARTV is +88.01%; over the trailing twelve months it is +262.96%. Its 52-week range spans $1.47 to $17.31. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces ARTV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own ARTV include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Artiva Biotherapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $7.81 |
| Market Cap | $447.98M |
| P/E Ratio | -2.27 |
| EPS | $-3.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $17.31 |
| 52-Week Low | $1.47 |
| Volume | 1.93K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-83.86M |
| Gross Margin | 0.00% |
6 analysts cover ARTV: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.